It is well know that tau hyperphosphorylation, mostly at serine (Ser) or threonine (Thr) residues, plays a crucial role in the pathogenesis of AD, thereby molecules that reduce phospho-tau aggregates may represent a good candidate for the AD treatment. Here, MAPT is linked to Alzheimer disease.